Time for new recommendations on cotrimoxazole prophylaxis for HIV-exposed infants in developing countries?
Department of Paediatrics and Child Health, University of KwaZulu-Natal, Private Bag 7, Congelia, 4013, South Africa. coutsoud@ukzn.ac.za
Anna
A
Coutsoudis
Hoosen M
HM
Coovadia
Gurpreet
G
Kindra
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002985:Clinical Protocols; D003906:Developing Countries; D015658:HIV Infections / Q000517:prevention & control / Q000635:transmission*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D045363:Pneumocystis carinii / Q000187:drug effects; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination